A brand-new federal multidistrict litigation docket is now open, and families across the United States are racing to understand their legal rights. On April 2, 2026, the Judicial Panel on Multidistrict Litigation officially created MDL No. 3178, consolidating lawsuits tied to the first-ever botulism outbreak in U.S. history linked to infant formula. If your baby consumed ByHeart Whole Nutrition Infant Formula and became ill, what happens next in this litigation could directly affect your family’s ability to recover compensation.
What Happened: The ByHeart Infant Formula Botulism Outbreak
The crisis began quietly in October 2025 when the California Department of Public Health identified a troubling pattern — three neonates in separate households had all been exposed to the same infant formula brand. That initial cluster triggered a joint investigation by the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration that would ultimately uncover the largest infant formula safety emergency in modern American history.
By November 8–11, 2025, ByHeart issued a full nationwide recall of its Whole Nutrition Infant Formula after federal health agencies formally linked the product to dozens of suspected or confirmed infant botulism cases spanning multiple states. The scale of the outbreak is unprecedented. Experts cited in national reporting have confirmed this is the first time a U.S. infant formula has ever been connected to a botulism outbreak — a distinction that makes the ByHeart infant formula lawsuit litigation uniquely significant from both a public health and legal standpoint.
On December 23, 2025, ByHeart’s laboratory partner IEH Laboratories completed testing of 36 finished product samples drawn from two recalled lots. The results were alarming: 6 of those 36 samples tested positive for Clostridium botulinum, the bacterium that produces the toxin responsible for botulism. The confirmed presence of the pathogen in finished product — formula that had already been sold and fed to infants — gave families and their attorneys the kind of direct laboratory evidence that rarely exists this early in mass tort litigation.
A subsequent FDA investigation identified the root cause: Clostridium botulinum contamination in organic whole-milk powder sourced from a Dairy Farmers of America processor and supplied by Organic West Milk. That supply-chain finding is legally significant because it extends potential liability beyond ByHeart itself to upstream ingredient suppliers, opening additional avenues of recovery for injured families.
When the CDC expanded its case definition on December 10, 2025, investigators extended the lookback window all the way to March 23, 2022 — the date ByHeart formula first became commercially available. That decision suggests that contamination may have been a persistent issue throughout the product’s market life, not an isolated manufacturing anomaly. Families who purchased ByHeart formula as far back as 2022 may have affected children without ever knowing the cause of their infant’s illness.
How Sick Infants Got: Botulism Symptoms and Hospitalizations
Infant botulism is among the most serious foodborne illnesses a newborn can develop. The toxin produced by Clostridium botulinum attacks the nervous system, and in infants — whose immune systems are not yet fully developed — the consequences can be life-altering. Symptoms reported in connection with the ByHeart infant formula lawsuit cases include constipation, progressive muscle weakness, poor feeding, labored breathing, and in severe cases, full paralysis. Many affected infants required prolonged hospitalizations, some spending weeks in intensive care units on mechanical ventilation.
According to the CDC and FDA, the outbreak was declared over on February 26, 2026, with a final confirmed case count of 28 confirmed and 20 probable infant botulism cases — 48 total, every one of them resulting in hospitalization. Critically, no deaths were reported. While that outcome is a measure of relief, the absence of fatalities does not diminish the severity of what these families endured. Infants diagnosed with botulism often require months of supportive care, including assisted ventilation, nasogastric tube feeding, and intensive physical and occupational therapy as the nervous system slowly recovers.
Cases were ultimately reported across 17 states: Arizona, California, Idaho, Illinois, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas, Virginia, Washington, and Wisconsin. The geographic breadth of the outbreak — stretching from the Pacific Coast to New England — reflects both the national distribution of ByHeart formula and the months-long window during which contaminated product remained on the market and in homes.
MDL 3178: What the New Federal Litigation Looks Like
MDL 3178 is now the central legal battleground for families harmed by the ByHeart infant formula botulism outbreak. The Judicial Panel on Multidistrict Litigation centralized the litigation in the Southern District of New York before the Honorable Judge Subramanian. Remarkably, consolidation was achieved in under five months from the initial recall to centralization — a pace that reflects both the urgency of the cases and the readiness of plaintiffs’ counsel to move quickly on behalf of injured infants and their families.
As of mid-2026, MDL 3178 has consolidated 19 actions: 9 individual injury cases brought on behalf of hospitalized infants and 10 economic-loss class actions filed by families who purchased recalled formula but whose children did not develop confirmed botulism. These two tracks — personal injury and economic loss — will likely proceed on different timescales, with the injury cases commanding the most immediate legal attention given the severity of harm involved.
The structure of the MDL means that while individual cases retain their identities, pretrial proceedings — including discovery, expert battles, and early dispositive motions — will be coordinated before a single judge. That efficiency benefits plaintiffs enormously. Rather than each family’s legal team independently seeking ByHeart’s internal testing records, manufacturing protocols, supply-chain documentation, and communications with the FDA, a consolidated plaintiffs’ steering committee will pursue that evidence on behalf of all injury claimants simultaneously.
One critical legal challenge that litigation observers are already flagging: no prior litigation template exists for this type of case. As Lawsuit Intelligencer reported in July 2026, there are no prior formula-botulism verdicts or established damages benchmarks for infant hospitalization injuries requiring months of supportive care. Plaintiffs’ attorneys will need to build damages frameworks largely from scratch, drawing on analogous cases involving other contaminated food products and serious pediatric injuries. That complexity makes early legal representation especially important for affected families.
ByHeart’s Regulatory History: The 2023 FDA Warning Letter
The botulism outbreak did not occur in a regulatory vacuum. In 2023, ByHeart received an FDA warning letter related to manufacturing and quality-control deficiencies at one of its facilities. ByHeart has maintained that the warning letter involved a facility separate from the one that produced the recalled lots at issue in the current litigation. That distinction matters legally — but it does not necessarily insulate the company from the broader narrative plaintiffs’ attorneys will construct about a manufacturer with a documented history of FDA scrutiny.
In mass tort litigation, regulatory history frequently plays a dual role. First, it can be used to establish a pattern of conduct — evidence that a company was aware of systemic quality-control vulnerabilities and failed to adequately address them. Second, it shapes the damages conversation. If plaintiffs can demonstrate that ByHeart had prior notice of sanitation or contamination risks and continued to market formula to the most vulnerable possible consumers — newborns — the case for enhanced compensatory or even punitive damages becomes substantially stronger.
The 2023 warning letter will almost certainly be a contested exhibit in MDL 3178. Defense counsel will work to limit its relevance to the specific facility and time period it addressed. Plaintiffs’ attorneys will argue it is probative of company-wide attitudes toward regulatory compliance. How Judge Subramanian ultimately rules on the admissibility and scope of that evidence could significantly shape the litigation’s trajectory heading into 2027.
Key Data: ByHeart Infant Formula Lawsuit and Outbreak Statistics
- 48 total cases (28 confirmed, 20 probable) — all hospitalized, no deaths — CDC/FDA, outbreak declared over February 26, 2026
- 17 states affected: Arizona, California, Idaho, Illinois, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas, Virginia, Washington, and Wisconsin
- Root cause: Clostridium botulinum in organic whole-milk powder from Dairy Farmers of America processor, supplied by Organic West Milk — FDA
- 6 of 36 finished product samples tested positive for Clostridium botulinum — IEH Laboratories, December 2025
- MDL 3178 centralized in S.D.N.Y. before Judge Subramanian, consolidating 19 actions (9 injury, 10 economic-loss class) in under five months from recall to centralization
- Lookback window extends to March 23, 2022 — the date ByHeart formula first entered commerce
- No prior litigation template: no formula-botulism verdicts or established damages benchmarks exist as of mid-2026 — Lawsuit Intelligencer
What Affected Families Must Do Right Now
If your infant consumed ByHeart Whole Nutrition Infant Formula and experienced any symptoms consistent with botulism — or if your child was hospitalized and botulism was considered as a possible diagnosis — the time to act is now. Mass tort litigation moves quickly once an MDL is established, and early participation in the process carries real advantages.
Preserve everything. Do not discard any remaining formula, packaging, or canisters. The lot number printed on the container is the key piece of physical evidence linking your purchase to the recalled product. Photograph the label, preserve the canister in a sealed bag, and store it somewhere safe. If you still have receipts, online order confirmations, or subscription records showing your ByHeart purchases, compile and save those as well.
Gather all medical records. Request complete records from every provider who treated your infant during the relevant period — pediatricians, emergency departments, hospital systems, and any specialists involved in your child’s care. Records documenting the timeline of symptoms, diagnostic testing, hospitalization duration, treatments administered, and any ongoing developmental concerns will form the medical backbone of your family’s legal claim.
Consult a mass tort attorney promptly. The creation of MDL 3178 means that organizational decisions about plaintiffs’ leadership and litigation strategy are being made right now. Families who retain experienced legal counsel early are better positioned to have their voices heard in those proceedings. Statutes of limitations vary by state, and while the lookback window extends to 2022, the clock on your ability to file is not unlimited.
Do not communicate directly with ByHeart or its insurers. If you are contacted by anyone representing the company, decline to provide statements or sign any documents without first consulting an attorney. Early settlement outreach in mass tort cases is common, and initial offers rarely reflect the full value of a family’s claim — particularly in a litigation landscape where, as of 2026, no damages benchmarks yet exist for this type of injury.
Frequently Asked Questions About the ByHeart Infant Formula Lawsuit
What is MDL 3178 and how does it affect my family’s ByHeart claim?
MDL 3178 is the federal multidistrict litigation created by the Judicial Panel on Multidistrict Litigation on April 2, 2026, to consolidate ByHeart infant formula botulism lawsuits filed across the country. The MDL is pending in the Southern District of New York before Judge Subramanian. Consolidation does not mean your family’s case disappears into a class action — individual injury claims retain their identities. What MDL consolidation does is coordinate pretrial proceedings so that discovery, expert testimony, and key legal rulings happen once, efficiently, rather than being relitigated in courtrooms across 17 states. Your family’s case will benefit from shared resources while still being evaluated on its specific facts and injuries when it comes time to resolve.
My baby had symptoms but was never diagnosed with botulism. Can I still file a ByHeart infant formula lawsuit?
Potentially, yes. Infant botulism is notoriously underdiagnosed. The symptoms — constipation, generalized weakness, poor feeding, floppy muscle tone — can mimic other conditions, and not every affected child will have received a definitive laboratory confirmation. Families whose infants showed symptoms consistent with botulism during the relevant period, who fed their baby ByHeart formula from recalled lots, may still have viable claims even without a formal diagnosis. An experienced mass tort attorney can help evaluate the strength of your potential claim based on the specific clinical history, timing, and lot numbers involved.
The recalled formula was purchased years ago. Is it too late to file a claim?
Not necessarily. The CDC’s lookback window extends to March 23, 2022, meaning that illnesses potentially linked to ByHeart formula stretch back to the product’s commercial launch. Whether a claim filed today is timely depends on your state’s statute of limitations for product liability or personal injury claims, and on when your child’s injury was — or reasonably should have been — discovered. Many states apply a discovery rule that tolls the limitations period until a plaintiff knew or had reason to know of the connection between the product and the injury. Given that the outbreak was not publicly identified until late 2025, families with affected children from earlier years may still be within the filing window. An attorney can assess your specific situation.
What compensation could families recover in a ByHeart infant formula lawsuit?
Families pursuing injury claims in MDL 3178 may seek compensation for medical expenses — including emergency care, ICU hospitalization, mechanical ventilation, and months of supportive care — as well as ongoing treatment costs, pain and suffering, developmental harm, and in appropriate cases, punitive damages. As Lawsuit Intelligencer noted in July 2026, no prior formula-botulism verdicts or established damages benchmarks exist, which means plaintiffs’ attorneys are building the damages framework for this litigation category from the ground up. That complexity cuts both ways: there is no ceiling set by prior verdicts, but there is also no floor. The severity of your child’s specific injuries, the duration of hospitalization, and the long-term prognosis will all be central to determining the value of your family’s individual claim.
ByHeart says the 2023 FDA warning letter involved a facility unrelated to the recalled formula. Does that hurt the lawsuits?
It complicates one piece of the evidentiary puzzle, but it does not undermine the litigation as a whole. Plaintiffs’ attorneys will argue that the 2023 warning letter is relevant to establishing ByHeart’s awareness of quality-control vulnerabilities across its manufacturing operations — and that a company with that regulatory history bore a heightened duty to ensure the safety of formula destined for newborns. Whether that argument succeeds will depend in large part on how Judge Subramanian rules on the admissibility of the warning letter evidence. Meanwhile, the direct laboratory confirmation of Clostridium botulinum in finished product samples — and the FDA’s identification of the contaminated milk powder supply chain — provide independent, powerful evidence of liability that stands entirely on its own.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.